Iovance Biotherapeutics(IOVA)
(IOVA)
Q4
58 dage siden‧49 min
Ordredybde
Lukket
Antal
Køb
14
Sælg
Antal
96
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| - | - | - | - |
Volumenvægtet gennemsnitspris
-VWAP
-Omsætning (USD)
-Mæglerstatistik
Ingen data fundet
Corporate Actions
| Næste begivenhed | |
|---|---|
Finanskalender er ikke tilgængelig | |
| Tidligere begivenheder | ||
|---|---|---|
| 2023 Q4 | 28. feb. | |
| 2023 Årsregnskab | 28. feb. | |
| 2023 Q3 | 7. nov. 2023 | |
| 2023 Q2 | 8. aug. 2023 | |
| 2023 Generalforsamling | 6. jun. 2023 |
Data hentes fra Morningstar, Quartr
Nyheder og Analyser
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Q4
58 dage siden‧49 min
Nyheder og Analyser
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Corporate Actions
| Næste begivenhed | |
|---|---|
Finanskalender er ikke tilgængelig | |
| Tidligere begivenheder | ||
|---|---|---|
| 2023 Q4 | 28. feb. | |
| 2023 Årsregnskab | 28. feb. | |
| 2023 Q3 | 7. nov. 2023 | |
| 2023 Q2 | 8. aug. 2023 | |
| 2023 Generalforsamling | 6. jun. 2023 |
Data hentes fra Morningstar, Quartr
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
29. feb.29. feb.Didn't quite meet expectationt. Didn' miss by a lot though? Any thoughts?
11. mar.11. mar.They didn't have an approved drug prior to this, so I am not sure if the previous expectations mean anything. It's the future sales of the drug that define the near future success. Long term depends on if they can expand their technology beyond melanoma and/or manage to have it approved and sold in other markets. It is a very costly drug, so countries with strong public healthcare will be difficult. That being said, many if not most European countries offer CAR T cell treatment already, despite the hefty price tag.- 27. feb.27. feb.What are your expectations for the upcoming interim report?
- 22. feb.22. feb.Dump and pump just wait 🤜
24. feb.24. feb.Solgte lidt ud og købte ANRO - NERV - ATNM. Men synes ikke at IOVA ligger op til en pump and dump. “Lang” - 21. feb.21. feb.It is important to note that this has the potential to be truly groundbreaking technology: until now there has not been any cell-based treatments for solid cancers (although Immunocore comes close with their ImmTACs, and they are doing well). Not even the hyped CAR-T cells have been effective against solid tumors. What's more, the TIL technology is, in theory, applicable to all respectable solid cancer types, although the ones with high neoantigen burden a more likely to respond.21. feb.21. feb.Hey Slug Hvad siger du så til immunity bio eller evaxion ? Køber lidt ind i Actinium Pharma i morgen inden phase 3.22. feb.22. feb.Hi there Whale, I have been more cautious with vaccine based cancer immunotherapies. The general idea is very promising, but the failure to deliver in this field by the big shots such as Biontech makes me think that some critical piece of the puzzle is still missing with this technology. The AI based neoantigen discovery by Evaxion looks interesting, but I am sure that e.g. Biontech know this approach as well. ImmunityBio reported nice clinical study data, but that is still far from the FDA approval. Once they file for that, I will surely reconsider my stance.
- Well, it seems that I got my prediction about the FDA approval right. Today near +40% at the open. Let's see where we go from here, so far so good.+25% the following day, a nice start indeed to the FDA-approved era.
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Q4
58 dage siden‧49 min
Nyheder og Analyser
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
- 29. feb.29. feb.Didn't quite meet expectationt. Didn' miss by a lot though? Any thoughts?11. mar.11. mar.They didn't have an approved drug prior to this, so I am not sure if the previous expectations mean anything. It's the future sales of the drug that define the near future success. Long term depends on if they can expand their technology beyond melanoma and/or manage to have it approved and sold in other markets. It is a very costly drug, so countries with strong public healthcare will be difficult. That being said, many if not most European countries offer CAR T cell treatment already, despite the hefty price tag.
- 27. feb.27. feb.What are your expectations for the upcoming interim report?
- 22. feb.22. feb.Dump and pump just wait 🤜24. feb.24. feb.Solgte lidt ud og købte ANRO - NERV - ATNM. Men synes ikke at IOVA ligger op til en pump and dump. “Lang”
- 21. feb.21. feb.It is important to note that this has the potential to be truly groundbreaking technology: until now there has not been any cell-based treatments for solid cancers (although Immunocore comes close with their ImmTACs, and they are doing well). Not even the hyped CAR-T cells have been effective against solid tumors. What's more, the TIL technology is, in theory, applicable to all respectable solid cancer types, although the ones with high neoantigen burden a more likely to respond.21. feb.21. feb.Hey Slug Hvad siger du så til immunity bio eller evaxion ? Køber lidt ind i Actinium Pharma i morgen inden phase 3.22. feb.22. feb.Hi there Whale, I have been more cautious with vaccine based cancer immunotherapies. The general idea is very promising, but the failure to deliver in this field by the big shots such as Biontech makes me think that some critical piece of the puzzle is still missing with this technology. The AI based neoantigen discovery by Evaxion looks interesting, but I am sure that e.g. Biontech know this approach as well. ImmunityBio reported nice clinical study data, but that is still far from the FDA approval. Once they file for that, I will surely reconsider my stance.
- Well, it seems that I got my prediction about the FDA approval right. Today near +40% at the open. Let's see where we go from here, so far so good.+25% the following day, a nice start indeed to the FDA-approved era.
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Ordredybde
Lukket
Antal
Køb
14
Sælg
Antal
96
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| - | - | - | - |
Volumenvægtet gennemsnitspris
-VWAP
-Omsætning (USD)
-Mæglerstatistik
Ingen data fundet
Corporate Actions
| Næste begivenhed | |
|---|---|
Finanskalender er ikke tilgængelig | |
| Tidligere begivenheder | ||
|---|---|---|
| 2023 Q4 | 28. feb. | |
| 2023 Årsregnskab | 28. feb. | |
| 2023 Q3 | 7. nov. 2023 | |
| 2023 Q2 | 8. aug. 2023 | |
| 2023 Generalforsamling | 6. jun. 2023 |
Data hentes fra Morningstar, Quartr